Contineum Therapeutics, Inc. (CTNM) Fair Value 2026

CTNM · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.0 /10

32 fundamental signals · 0 models active

Value Trap Risk

SAFE (21/100)

Quick Summary — As of 2026-08-28, Contineum Therapeutics, Inc. (CTNM) trades at $17.05. QOC: 5.0/10. Value Trap Risk: 21/100 (SAFE). 0/13 models active.

Key Facts

Ticker
CTNM
Price
$17.05
Quality Score
5.0/10
Value Trap Risk
21/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Below-average Quality Score of 5.0/10 signals weak fundamentals

What Fair Value Does Each Model Give CTNM?

0 Intrinsic Value Models vs. Current Price ($17.05)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Contineum Therapeutics, Inc. (CTNM) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Contineum Therapeutics, Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About CTNM?

0 of 13 models are currently active for CTNM. See which stocks rank higher →

How Does CTNM Rank in Biotechnology?

Among 625 Biotechnology stocks, CTNM ranks #327 by Quality of Company score. CirclFi's QOC score of 5.0/10 evaluates 32 fundamental signals. A score of 5.0 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

Contineum Therapeutics, Inc.'s positioning within the Biotechnology segment means that clinical trial success rate plays an outsized role in fundamental analysis. The sector's unique characteristics — including first-mover advantage in novel targets — shape both the opportunity set and risk profile.

Is CTNM a Value Trap?

CirclFi's Value Trap algorithm assigns CTNM a score of 21/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Contineum Therapeutics, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Contineum Therapeutics, Inc. earns a quality score of 5.0/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every CTNM valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Contineum Therapeutics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

GNTAGenenta Science S.p.A.QOC 5.0DRUGBright Minds Biosciences Inc.QOC 5.0TCRTAlaunos Therapeutics, Inc.QOC 5.0GHRSGH Research PLCQOC 5.0KODKodiak Sciences Inc.QOC 5.0COGTCogent Biosciences, Inc.QOC 5.0JBIOJade Biosciences, Inc.QOC 4.3MDXGMiMedx Group, Inc.QOC 8.7PRLDPrelude Therapeutics IncorporatedQOC 5.8EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: GNTA · DRUG · TCRT · GHRS · KOD · COGT · JBIO · MDXG · PRLD · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to CTNM?

6 companies across all industries closest to CTNM’s Quality of Company score of 5.0/10.

GRMLGreenland Mines LtdQOC 5.0OZBelpointe PREP, LLCQOC 5.0URSBURSB Bancorp, Inc.QOC 5.0VFSVinFast Auto Ltd.QOC 5.0DEFTDeFi Technologies Inc.QOC 5.0NVDANVIDIA CorporationQOC 10.0

Read investment analysis: GRML · OZ · URSB · VFS · DEFT · NVDA

Where Does CTNM Sit in CirclFi's Biotechnology Rankings?

CTNM is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Contineum Therapeutics, Inc.’s Valuation?

What is Contineum Therapeutics, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Contineum Therapeutics, Inc. (CTNM). The Quality of Company score is 5.0/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is CTNM overvalued or undervalued right now?

At $17.05, 0 of 0 active models suggest CTNM may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Contineum Therapeutics, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 5.0 mean for CTNM?

Contineum Therapeutics, Inc.'s QOC of 5.0/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on CTNM?

CirclFi analyzes CTNM with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is CTNM a value trap in 2026?

Contineum Therapeutics, Inc.'s Value Trap score is 21/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Contineum Therapeutics, Inc. (CTNM) a Quality of Company score of 5.0/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/CTNM/ · Methodology
Primary sources for this CTNM valuation
  • Financial statements: Contineum Therapeutics, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001855175) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for CTNM as of ; valuations recomputed .